These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 25174872)

  • 21. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.
    Mérino D; Khaw SL; Glaser SP; Anderson DJ; Belmont LD; Wong C; Yue P; Robati M; Phipson B; Fairlie WD; Lee EF; Campbell KJ; Vandenberg CJ; Cory S; Roberts AW; Ludlam MJ; Huang DC; Bouillet P
    Blood; 2012 Jun; 119(24):5807-16. PubMed ID: 22538851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenström macroglobulinemia.
    Gaudette BT; Dwivedi B; Chitta KS; Poulain S; Powell D; Vertino P; Leleu X; Lonial S; Chanan-Khan AA; Kowalski J; Boise LH
    Oncogene; 2016 Jan; 35(4):479-90. PubMed ID: 25893290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells.
    Will B; Siddiqi T; Jordà MA; Shimamura T; Luptakova K; Staber PB; Costa DB; Steidl U; Tenen DG; Kobayashi S
    Blood; 2010 Apr; 115(14):2901-9. PubMed ID: 20160166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.
    Kuroda J; Puthalakath H; Cragg MS; Kelly PN; Bouillet P; Huang DC; Kimura S; Ottmann OG; Druker BJ; Villunger A; Roberts AW; Strasser A
    Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14907-12. PubMed ID: 16997913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The induction of Bim expression in human T-cell blasts is dependent on nonapoptotic Fas/CD95 signaling.
    Bosque A; Aguiló JI; Alava MA; Paz-Artal E; Naval J; Allende LM; Anel A
    Blood; 2007 Feb; 109(4):1627-35. PubMed ID: 17062728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner.
    Kiprianova I; Remy J; Milosch N; Mohrenz IV; Seifert V; Aigner A; Kögel D
    Neoplasia; 2015 Jul; 17(7):564-73. PubMed ID: 26297434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interactions of pro-apoptotic BH3 proteins with anti-apoptotic Bcl-2 family proteins measured in live MCF-7 cells using FLIM FRET.
    Liu Q; Leber B; Andrews DW
    Cell Cycle; 2012 Oct; 11(19):3536-42. PubMed ID: 22895112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.
    Cragg MS; Jansen ES; Cook M; Harris C; Strasser A; Scott CL
    J Clin Invest; 2008 Nov; 118(11):3651-9. PubMed ID: 18949058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1.
    Campone M; Noël B; Couriaud C; Grau M; Guillemin Y; Gautier F; Gouraud W; Charbonnel C; Campion L; Jézéquel P; Braun F; Barré B; Coqueret O; Barillé-Nion S; Juin P
    Mol Cancer; 2011 Sep; 10():110. PubMed ID: 21899728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.
    Tahir SK; Yang X; Anderson MG; Morgan-Lappe SE; Sarthy AV; Chen J; Warner RB; Ng SC; Fesik SW; Elmore SW; Rosenberg SH; Tse C
    Cancer Res; 2007 Feb; 67(3):1176-83. PubMed ID: 17283153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.
    Del Gaizo Moore V; Brown JR; Certo M; Love TM; Novina CD; Letai A
    J Clin Invest; 2007 Jan; 117(1):112-21. PubMed ID: 17200714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preferential control of induced regulatory T cell homeostasis via a Bim/Bcl-2 axis.
    Wang X; Szymczak-Workman AL; Gravano DM; Workman CJ; Green DR; Vignali DA
    Cell Death Dis; 2012 Feb; 3(2):e270. PubMed ID: 22318539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 2-deoxyglucose-induced toxicity is regulated by Bcl-2 family members and is enhanced by antagonizing Bcl-2 in lymphoma cell lines.
    Zagorodna O; Martin SM; Rutkowski DT; Kuwana T; Spitz DR; Knudson CM
    Oncogene; 2012 May; 31(22):2738-49. PubMed ID: 21986940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells.
    Gomez-Bougie P; Bataille R; Amiot M
    Eur J Immunol; 2004 Nov; 34(11):3156-64. PubMed ID: 15459900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia.
    Ko TK; Chin HS; Chuah CT; Huang JW; Ng KP; Khaw SL; Huang DC; Ong ST
    Oncotarget; 2016 Jan; 7(3):2721-33. PubMed ID: 26517680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Critical role for BIM in T cell receptor restimulation-induced death.
    Snow AL; Oliveira JB; Zheng L; Dale JK; Fleisher TA; Lenardo MJ
    Biol Direct; 2008 Aug; 3():34. PubMed ID: 18715501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors.
    Kiyota M; Kuroda J; Yamamoto-Sugitani M; Shimura Y; Nakayama R; Nagoshi H; Mizutani S; Chinen Y; Sasaki N; Sakamoto N; Kobayashi T; Matsumoto Y; Horiike S; Taniwaki M
    Apoptosis; 2013 Nov; 18(11):1437-1446. PubMed ID: 23851982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737.
    Hauck P; Chao BH; Litz J; Krystal GW
    Mol Cancer Ther; 2009 Apr; 8(4):883-92. PubMed ID: 19372561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.
    Pétigny-Lechartier C; Duboc C; Jebahi A; Louis MH; Abeilard E; Denoyelle C; Gauduchon P; Poulain L; Villedieu M
    Mol Cancer Ther; 2017 Jan; 16(1):102-115. PubMed ID: 27980105
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bim-Bcl-2 homology 3 mimetic therapy is effective at suppressing inflammatory arthritis through the activation of myeloid cell apoptosis.
    Scatizzi JC; Hutcheson J; Pope RM; Firestein GS; Koch AE; Mavers M; Smason A; Agrawal H; Haines GK; Chandel NS; Hotchkiss RS; Perlman H
    Arthritis Rheum; 2010 Feb; 62(2):441-51. PubMed ID: 20112357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.